Peptides Similar to GUBamy
Compare GUBamy with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Pramlintide: High - Both are amylin receptor agonists. Pramlintide is the only approved amylin analog. GUBamy additionally activates calcitonin receptors (DACRA) and has a dramatically longer half-life.
- •Cagrilintide: High - Both are long-acting amylin analogs with weekly dosing. Both target obesity. Cagrilintide is AMY-selective; GUBamy is a DACRA (also activates calcitonin receptors).
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| GUBamy (current) | - | - |
| Pramlintide | High - Both are amylin receptor agonists. Pramlintide is the only approved amylin analog. GUBamy additionally activates calcitonin receptors (DACRA) and has a dramatically longer half-life. | Pramlintide requires thrice-daily injection (48-min half-life) vs weekly for GUBamy (11-day half-life). Pramlintide is AMY-selective; GUBamy is a DACRA. Pramlintide is approved for diabetes adjunct; GUBamy targets obesity. |
| Cagrilintide | High - Both are long-acting amylin analogs with weekly dosing. Both target obesity. Cagrilintide is AMY-selective; GUBamy is a DACRA (also activates calcitonin receptors). | Cagrilintide is being developed primarily as combination therapy with semaglutide (CagriSema). GUBamy has DACRA activity while cagrilintide is AMY-selective. Different development partners (Novo Nordisk vs AbbVie). |
| Petrelintide | High - Both are next-generation long-acting amylin analogs targeting obesity. Both aim to provide meaningful weight loss through amylin-pathway activation with convenient dosing. | GUBamy is a DACRA (dual amylin + calcitonin); petrelintide receptor selectivity profile may differ. Different developers (Gubra/AbbVie vs Zealand Pharma). Different stages of development. |
PramlintideHigh - Both are amylin receptor agonists. Pramlintide is the only approved amylin analog. GUBamy additionally activates calcitonin receptors (DACRA) and has a dramatically longer half-life.
Differences
Pramlintide requires thrice-daily injection (48-min half-life) vs weekly for GUBamy (11-day half-life). Pramlintide is AMY-selective; GUBamy is a DACRA. Pramlintide is approved for diabetes adjunct; GUBamy targets obesity.
Advantages
Once-weekly dosing vs thrice-daily. Dual receptor activation may provide superior weight loss. Greater weight loss potential (7.77% at day 43 in phase 1).
Disadvantages
Phase 1 only (pramlintide is FDA-approved). Extremely limited safety data. No diabetes indication data. Not yet commercially available.
CagrilintideHigh - Both are long-acting amylin analogs with weekly dosing. Both target obesity. Cagrilintide is AMY-selective; GUBamy is a DACRA (also activates calcitonin receptors).
Differences
Cagrilintide is being developed primarily as combination therapy with semaglutide (CagriSema). GUBamy has DACRA activity while cagrilintide is AMY-selective. Different development partners (Novo Nordisk vs AbbVie).
Advantages
DACRA mechanism may provide additional metabolic benefits beyond AMY-selective agonism. Longer half-life (11 days vs 7 days).
Disadvantages
Much earlier in development (phase 1 vs phase 3 for CagriSema). No combination data with GLP-1 RAs yet. Less clinical experience.
PetrelintideHigh - Both are next-generation long-acting amylin analogs targeting obesity. Both aim to provide meaningful weight loss through amylin-pathway activation with convenient dosing.
Differences
GUBamy is a DACRA (dual amylin + calcitonin); petrelintide receptor selectivity profile may differ. Different developers (Gubra/AbbVie vs Zealand Pharma). Different stages of development.
Advantages
AbbVie partnership provides substantial development resources. Phase 1 weight loss data (7.77% at day 43) is promising.
Disadvantages
Both are early-stage with limited clinical data. Direct comparison is not possible at this stage.
Peptides Related to GUBamy#
GUBamy is part of the emerging amylin-class therapeutic landscape for obesity. The amylin pathway has gained significant pharmaceutical interest as a complement to GLP-1 receptor agonism, with multiple companies developing long-acting amylin analogs. GUBamy is distinguished as a DACRA (dual amylin and calcitonin receptor agonist) rather than an AMY-selective agent.
Pramlintide (Symlin)#
Pramlintide is the only FDA-approved amylin analog and the foundational reference for the amylin class. Approved in 2005 as an adjunct to insulin for type 1 and type 2 diabetes, it demonstrates the therapeutic potential of amylin agonism but is limited by its short half-life.
Mechanism comparison: Both activate amylin receptors to reduce appetite and delay gastric emptying. Pramlintide is primarily AMY-selective, while GUBamy additionally activates calcitonin receptors. This dual receptor activation (DACRA) may provide metabolic benefits beyond what AMY-selective agents achieve.
Practical comparison: The most dramatic difference is dosing convenience. Pramlintide's 48-minute half-life requires injection before each meal (3x daily), which contributed to its limited commercial adoption despite clear metabolic benefits. GUBamy's 11-day half-life enables once-weekly dosing.
| Parameter | Pramlintide | GUBamy |
|---|---|---|
| Half-life | ~48 minutes | ~11 days |
| Dosing | 3x daily (before meals) | Once weekly |
| Receptor profile | AMY-selective | DACRA (AMY + CTR) |
| Indication | Diabetes (adjunct to insulin) | Obesity (target) |
| Regulatory status | FDA-approved (2005) | Phase 1 |
| Max weight loss | ~2-3 kg (adjunct to insulin) | -7.77% at day 43 |
Cagrilintide (Novo Nordisk)#
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk, primarily as the amylin component of CagriSema (cagrilintide + semaglutide combination).
Mechanism comparison: Both are long-acting amylin analogs with weekly dosing. The key mechanistic difference is that cagrilintide is AMY-selective while GUBamy additionally activates calcitonin receptors. Whether DACRA activity provides clinically meaningful advantages over AMY-selective agonism is an open question.
Development strategy: Cagrilintide's primary value proposition is in combination with semaglutide (CagriSema), which has shown weight loss exceeding 20% in phase 3 trials. GUBamy is similarly expected to be developed in combination with GLP-1 RAs, though no clinical combination data exist yet.
Petrelintide (Zealand Pharma)#
Petrelintide is a long-acting amylin analog in development by Zealand Pharma. It is being positioned as a potential competitor to cagrilintide, with claims of better tolerability and muscle preservation properties.
Key comparison: Both GUBamy and petrelintide represent next-generation amylin analogs from Nordic biotechnology companies. Direct comparison is premature given the early stage of both programs.
Amycretin (Novo Nordisk)#
Amycretin is a single-molecule co-agonist of amylin and GLP-1 receptors. Unlike GUBamy (which would need to be combined separately with a GLP-1 RA), amycretin combines both mechanisms in one peptide.
Key trade-off: Amycretin's single-molecule approach is simpler from a development and dosing perspective, but limits the ability to independently titrate each mechanism. GUBamy as a separate molecule offers the flexibility of dose-independent combination.
Summary Comparison#
| Feature | GUBamy | Pramlintide | Cagrilintide | Petrelintide | Amycretin |
|---|---|---|---|---|---|
| Class | DACRA | AMY agonist | AMY agonist | AMY agonist | AMY + GLP-1 |
| Half-life | ~11 days | ~48 min | ~7 days | Extended | Extended |
| Dosing | QW | TID | QW | QW or less | QW |
| Phase | Phase 1 | Approved | Phase 3 (combo) | Phase 2 | Phase 1/2 |
| Developer | Gubra/AbbVie | Various | Novo Nordisk | Zealand | Novo Nordisk |
| Key differentiator | DACRA + long t1/2 | First-in-class | CagriSema combo | Muscle preservation | Single molecule |
Related Reading#
Frequently Asked Questions About GUBamy
What are the main alternatives to GUBamy?
The primary alternatives to GUBamy include Pramlintide, Cagrilintide, Petrelintide. Each has a different mechanism of action and evidence profile. The choice between them depends on the specific research objectives.
How does GUBamy compare to Pramlintide?
High - Both are amylin receptor agonists. Pramlintide is the only approved amylin analog. GUBamy additionally activates calcitonin receptors (DACRA) and has a dramatically longer half-life.. Key differences: Pramlintide requires thrice-daily injection (48-min half-life) vs weekly for GUBamy (11-day half-life). Pramlintide is AMY-selective; GUBamy is a DACRA. Pramlintide is approved for diabetes adjunct; GUBamy targets obesity.. Advantages of Pramlintide: Once-weekly dosing vs thrice-daily. Dual receptor activation may provide superior weight loss. Greater weight loss potential (7.77% at day 43 in phase 1).. Disadvantages: Phase 1 only (pramlintide is FDA-approved). Extremely limited safety data. No diabetes indication data. Not yet commercially available..
How does GUBamy compare to Cagrilintide?
High - Both are long-acting amylin analogs with weekly dosing. Both target obesity. Cagrilintide is AMY-selective; GUBamy is a DACRA (also activates calcitonin receptors).. Key differences: Cagrilintide is being developed primarily as combination therapy with semaglutide (CagriSema). GUBamy has DACRA activity while cagrilintide is AMY-selective. Different development partners (Novo Nordisk vs AbbVie).. Advantages of Cagrilintide: DACRA mechanism may provide additional metabolic benefits beyond AMY-selective agonism. Longer half-life (11 days vs 7 days).. Disadvantages: Much earlier in development (phase 1 vs phase 3 for CagriSema). No combination data with GLP-1 RAs yet. Less clinical experience..
Can GUBamy be combined with other peptides?
Some research protocols study GUBamy in combination with related peptides such as Pramlintide, Cagrilintide, Petrelintide. However, combination studies are limited and no established guidelines exist for combining these peptides. Any combination use should be guided by available research data.
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer